Literature DB >> 8933332

Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites.

F Durocher1, P Tonin, D Shattuck-Eidens, M Skolnick, S A Narod, J Simard.   

Abstract

Germline mutations in the BRCA1 tumour suppressor gene on chromosome 17q21 are responsible for approximately half of the cases of hereditary breast cancer, including the majority of familial breast/ovarian cancers. To increase our knowledge of the spectrum of BRCA1 mutations, we have extended our analysis to include patients with varied family histories of cancer of the breast, ovary, and at multiple other sites. We have analysed 23 unrelated familial cases using direct sequencing or a combination of dideoxy fingerprinting and sequencing procedures. Twenty one of these families contained three or more cases of breast or ovarian cancer and two families had one case of breast cancer diagnosed before the age of 40 and one case of ovarian cancer. The common frameshift mutation 5382insC was detected in two patients, and the 185delAG mutation was found in a family of Ashkenazi Jewish descent. The novel frameshift mutation 3450del4 (CAAG) was detected in a patient who developed breast cancer at the age of 28 and ovarian cancer at the age of 34. Three other women in this family were diagnosed with breast cancer at the ages of 26, 29, and 40. The novel framshift mutation 2953del3+C was found in a French Canadian woman who had developed two primary cancers of the breast at the age of 37 and 38 and renal cancer at the age of 38.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933332      PMCID: PMC1050758          DOI: 10.1136/jmg.33.10.814

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  49 in total

1.  Dideoxy fingerprinting (ddE): a rapid and efficient screen for the presence of mutations.

Authors:  G Sarkar; H S Yoon; S S Sommer
Journal:  Genomics       Date:  1992-06       Impact factor: 5.736

2.  Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations.

Authors:  F Durocher; D Shattuck-Eidens; M McClure; F Labrie; M H Skolnick; D E Goldgar; J Simard
Journal:  Hum Mol Genet       Date:  1996-06       Impact factor: 6.150

3.  Familial breast-ovarian cancer locus on chromosome 17q12-q23.

Authors:  S A Narod; J Feunteun; H T Lynch; P Watson; T Conway; J Lynch; G M Lenoir
Journal:  Lancet       Date:  1991-07-13       Impact factor: 79.321

Review 4.  Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing.

Authors:  W D Foulkes; S A Narod
Journal:  Clin Invest Med       Date:  1995-12       Impact factor: 0.825

5.  Linkage of early-onset familial breast cancer to chromosome 17q21.

Authors:  J M Hall; M K Lee; B Newman; J E Morrow; L A Anderson; B Huey; M C King
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

6.  Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group.

Authors:  S A Gayther; P Harrington; P Russell; G Kharkevich; R F Garkavtseva; B A Ponder
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

7.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

8.  Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.

Authors:  C M Phelan; T R Rebbeck; B L Weber; P Devilee; M H Ruttledge; H T Lynch; G M Lenoir; M R Stratton; D F Easton; B A Ponder; L Cannon-Albright; C Larsson; D E Goldgar; S A Narod
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

9.  Growth retardation and tumour inhibition by BRCA1.

Authors:  J T Holt; M E Thompson; C Szabo; C Robinson-Benion; C L Arteaga; M C King; R A Jensen
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

10.  Genetic analysis of breast cancer in the cancer and steroid hormone study.

Authors:  E B Claus; N Risch; W D Thompson
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

View more
  12 in total

1.  BRCA1 variants in a family study of African-American and Latina women.

Authors:  Roberta McKean-Cowdin; Heather Spencer Feigelson; Lucy Y Xia; Celeste Leigh Pearce; Duncan C Thomas; Daniel O Stram; Brian E Henderson
Journal:  Hum Genet       Date:  2005-02-23       Impact factor: 4.132

2.  Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

Authors:  Jacques Simard; Martine Dumont; Anne-Marie Moisan; Valérie Gaborieau; Hélène Malouin; Francine Durocher; Jocelyne Chiquette; Marie Plante; Denise Avard; Paul Bessette; Claire Brousseau; Michel Dorval; Béatrice Godard; Louis Houde; Yann Joly; Marie-Andrée Lajoie; Gilles Leblanc; Jean Lépine; Bernard Lespérance; Hélène Vézina; Jillian Parboosingh; Roxane Pichette; Louise Provencher; Josée Rhéaume; Daniel Sinnett; Carolle Samson; Jean-Claude Simard; Martine Tranchant; Patricia Voyer; Douglas Easton; Sean V Tavtigian; Bartha-Maria Knoppers; Rachel Laframboise; Peter Bridge; David Goldgar
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

3.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

4.  Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?

Authors:  Sara Levene; Gillian Scott; Patricia Price; Jeremy Sanderson; Helen Evans; Claire Taylor; Sylvia Bass; Cathryn Lewis; Shirley Hodgson
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

5.  Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.

Authors:  Sean P Cleary; Hyeja Kim; Marina E Croitoru; Mark Redston; Julia A Knight; Steven Gallinger; Robert Gryfe
Journal:  Dis Colon Rectum       Date:  2008-07-10       Impact factor: 4.585

6.  Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.

Authors:  C Li; J Ao; J Fu; D-F Lee; J Xu; D Lonard; B W O'Malley
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

7.  The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.

Authors:  Teresa M Rudkin; Nancy Hamel; Maria Galvez; Frans Hogervorst; Johan J P Gille; Pål Møller; Jaran Apold; William D Foulkes
Journal:  BMC Med Genet       Date:  2006-03-01       Impact factor: 2.103

8.  Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.

Authors:  Pedro Pinto; Ana Peixoto; Catarina Santos; Patrícia Rocha; Carla Pinto; Manuela Pinheiro; Luís Leça; Ana Teresa Martins; Verónica Ferreira; Carla Bartosch; Manuel R Teixeira
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

9.  Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).

Authors:  Pilar Blay; Iñigo Santamaría; Ana S Pitiot; María Luque; Marta G Alvarado; Ana Lastra; Yolanda Fernández; Angeles Paredes; José M P Freije; Milagros Balbín
Journal:  BMC Cancer       Date:  2013-05-17       Impact factor: 4.430

10.  Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.

Authors:  Felipe C Silva; Bianca Cg Lisboa; Marcia Cp Figueiredo; Giovana T Torrezan; Erika Mm Santos; Ana C Krepischi; Benedito M Rossi; Maria I Achatz; Dirce M Carraro
Journal:  BMC Med Genet       Date:  2014-05-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.